Safety and Efficacy of Lumiracoxib Versus Naproxen in Acute Musculoskeletal Pain
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is designed to develop our understanding of the risk-benefit of using lumiracoxib
in patients with acute musculoskeletal pain due to uncomplicated soft tissue injury.